Amgen was the frontrunner among US Humira (adalimumab) biosimilar competitors in 2023, launching its Amjevita (adalimumab-atto) biosimilar at the end of January and gaining a five-month head start on its numerous rivals.
However, while this early launch delivered $51m in US sales during the two-month period that it was available in the...






